DEF 14C: Rani Therapeutics Secures $4.3M Capital Through Discounted Warrant Exercise Amidst Going Concern Doubt

Rani Therapeutics Holdings, Inc. announced a private placement transaction where an existing institutional investor exercised warrants at a reduced price, providing $4.3 million in gross proceeds, and received new warrants, with the issuance of underlying shares approved by a majority stockholder to address capital needs and going concern doubt.

Summary

• Rani Therapeutics Holdings, Inc. (the Company) entered into a Letter Agreement on May 20, 2025, with an existing institutional investor (the Investor).
• The Investor exercised existing Series B and Series C warrants for cash at a reduced exercise price of $0.65 per share.
• Gross proceeds of approximately $4.3 million were received from the exercise of Series B (3,246,753 shares) and Series C (3,333,333 shares) warrants.
• In consideration for the warrant exercises, the Company issued a new Series D common stock warrant to the Investor, allowing the purchase of 13,160,172 shares of Class A common stock at $0.65 per share.
• The issuance of shares upon exercise of the Series D Warrant required stockholder approval in accordance with Nasdaq Listing Rule 5635(d).
• On June 27, 2025, a stockholder holding approximately 80% of the voting rights (the Majority Holder) approved the Warrant Share Issuance by written consent in lieu of a meeting of stockholders.
• The Company's Board approved the issuance of the shares of Class A Common Stock issuable upon exercise of the Series D Warrant on May 19, 2025, subject to obtaining the required Stockholder Approval.
• The Company intends to use the net proceeds from the transaction for working capital and other general corporate purposes during the year ending December 31, 2025.
• As of March 31, 2025, the Company's cash, cash equivalents, and marketable securities totaled $15.9 million.
• The Company noted substantial doubt regarding its ability to continue as a going concern for a period of 12 months after the date its financial statements for the three months ended March 31, 2025, were issued, due to anticipated continued operating losses.
• Maxim Group LLC acted as the Company's financial advisor for the transaction, receiving an aggregate cash fee equal to 5.25% of the gross proceeds received from the warrant exercises.

Sentiment

Score: 3

Explanation: While the company successfully raised capital, the underlying reasons (explicit going concern doubt, heavily discounted warrant exercises, and significant potential dilution from new warrants) indicate a distressed financial situation and high operational risk. The capital raise is a necessity for survival rather than a sign of strong growth.

Positives

• Secured approximately $4.3 million in gross proceeds from the exercise of existing warrants, providing additional capital for operations.
• Obtained the necessary stockholder approval for the issuance of shares underlying the new Series D Warrant, ensuring compliance with Nasdaq Listing Rule 5635(d).
• The capital raise is intended to fund working capital and other general corporate purposes through the year ending December 31, 2025.
• Utilized a written consent from the Majority Holder to expedite the stockholder approval process, reducing costs and management time compared to holding a special meeting.

Negatives

• The Company disclosed substantial doubt regarding its ability to continue as a going concern for the next 12 months as of March 31, 2025, due to anticipated continued operating losses.
• Existing stockholders will incur dilution of their percentage ownership to the extent the Investor exercises the newly issued Series D Warrant.
• The exercise price for the new Series D Warrant and the reduced exercise price for the Series B and Series C warrants ($0.65 per share) are significantly lower than their original prices ($3.08 and $3.00 respectively), indicating a distressed capital raise.
• A financial advisory fee of 5.25% of the gross proceeds was paid, reducing the net capital received by the Company.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern for a period of 12 months after March 31, 2025, due to anticipated continued operating losses.
• Future dilution of percentage ownership for existing stockholders will occur if the Investor exercises the Series D Warrant.
• The Investor could significantly influence the Company's future decisions as long as it beneficially owns, or is able to beneficially own, a significant amount of Class A Common Stock.
• The Company anticipates continued operating losses and expects to rely on future equity or debt offerings or strategic transactions to meet its financial needs.

Future Outlook

The Company anticipates continued operating losses and expects to continue raising funds through equity or debt offerings or strategic transactions to meet its financial needs. The net proceeds from the current transaction are intended for working capital and other general corporate purposes during the year ending December 31, 2025.

Management Comments

• Our Board determined to pursue stockholder action by majority written consent of those shares entitled to vote in an effort to reduce the costs and management time required to hold a meeting of stockholders and to implement the above action in a timely manner.

Industry Context

This transaction is a common method for biotechnology and pharmaceutical companies, particularly those in the R&D or clinical stages like Rani Therapeutics, to raise necessary capital. The need for immediate funds, evidenced by the reduced warrant exercise prices and the issuance of new warrants, is typical for companies facing significant operating losses and long development cycles. The explicit 'going concern' warning is also a frequent disclosure in this industry, reflecting the high burn rates and reliance on external financing before product commercialization.

Comparison to Industry Standards

• The capital raise through warrant inducement, involving reduced exercise prices and the issuance of new warrants, is a common financing strategy for pre-revenue or early-revenue biotechnology companies, similar to approaches taken by companies like Athersys (ATHX) or Sorrento Therapeutics (SRNEQ) in their earlier stages to fund ongoing operations and clinical trials.
• The 'going concern' disclosure is a standard audit finding for many clinical-stage biotech companies that are not yet profitable, reflecting the inherent financial risks and reliance on continuous capital raises, comparable to disclosures made by companies such as Vaxart (VXRT) or Cassava Sciences (SAVA) when facing similar financial pressures.
• The 5.25% financial advisory fee paid to Maxim Group LLC is within the typical range for such capital-raising transactions in the biotechnology sector, although specific fees can vary based on deal size, complexity, and market conditions.
• The use of a majority stockholder written consent to approve the warrant issuance is a standard corporate governance mechanism under Delaware law and Nasdaq rules, frequently employed by companies to expedite financing rounds and other corporate actions without the time and expense associated with a full shareholder meeting.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution of their percentage ownership to the extent the Series D Warrant is exercised. The Majority Holder's significant voting power (approximately 80%) allows for swift corporate actions without broader shareholder vote.
• Creditors: The capital raise provides additional working capital, potentially improving the company's short-term liquidity and ability to meet obligations, although the going concern warning indicates ongoing financial challenges.
• Management/Employees: The capital infusion provides continued funding for operations, which may help secure jobs and ongoing projects, but the underlying financial distress remains a concern.

Next Steps

• The actions taken by written consent will not become effective until 20 calendar days after the Information Statement is first mailed (on or about July 10, 2025).
• Following the 20-day effectiveness period, the Investor will be able to exercise the Series D Warrant, subject to its terms and conditions.
• The Company expects to continue raising funds through equity or debt offerings or strategic transactions due to anticipated continued operating losses.

Key Dates

Recommendation

Keywords

Rani Therapeutics, SEC filing, DEF 14C, warrant exercise, Series D Warrant, capital raise, private placement, Nasdaq Listing Rule 5635(d), stockholder approval, going concern, dilution, Class A Common Stock, Class B Common Stock, financial advisory fees